PL3672622T3 - Rekombinowana ludzka kwaśna sfingomielinaza do zastosowania w leczeniu nieprawidłowych stanów kości u pacjentów z niedoborem kwaśnej sfingomielinazy - Google Patents

Rekombinowana ludzka kwaśna sfingomielinaza do zastosowania w leczeniu nieprawidłowych stanów kości u pacjentów z niedoborem kwaśnej sfingomielinazy

Info

Publication number
PL3672622T3
PL3672622T3 PL18768948.4T PL18768948T PL3672622T3 PL 3672622 T3 PL3672622 T3 PL 3672622T3 PL 18768948 T PL18768948 T PL 18768948T PL 3672622 T3 PL3672622 T3 PL 3672622T3
Authority
PL
Poland
Prior art keywords
acid sphingomyelinase
recombinant human
abnormal bone
treating abnormal
bone conditions
Prior art date
Application number
PL18768948.4T
Other languages
English (en)
Polish (pl)
Inventor
Ana Cristina SCHEIDT-PUGA
Original Assignee
Genzyme Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corporation filed Critical Genzyme Corporation
Publication of PL3672622T3 publication Critical patent/PL3672622T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
PL18768948.4T 2017-08-24 2018-08-22 Rekombinowana ludzka kwaśna sfingomielinaza do zastosowania w leczeniu nieprawidłowych stanów kości u pacjentów z niedoborem kwaśnej sfingomielinazy PL3672622T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762549732P 2017-08-24 2017-08-24
EP17306720 2017-12-07
PCT/IB2018/056346 WO2019038685A2 (en) 2017-08-24 2018-08-22 TREATMENT OF ABNORMAL BONE CONDITIONS IN PATIENTS WITH ACIDIC SPHINGOMYELASE DISEASE

Publications (1)

Publication Number Publication Date
PL3672622T3 true PL3672622T3 (pl) 2024-04-02

Family

ID=63556374

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18768948.4T PL3672622T3 (pl) 2017-08-24 2018-08-22 Rekombinowana ludzka kwaśna sfingomielinaza do zastosowania w leczeniu nieprawidłowych stanów kości u pacjentów z niedoborem kwaśnej sfingomielinazy

Country Status (16)

Country Link
US (2) US11898175B2 (enExample)
EP (1) EP3672622B1 (enExample)
JP (3) JP7216075B2 (enExample)
KR (2) KR102769578B1 (enExample)
CN (2) CN118453843A (enExample)
AU (2) AU2018319565B2 (enExample)
BR (1) BR112020003541A2 (enExample)
CA (1) CA3073648A1 (enExample)
CO (1) CO2020001801A2 (enExample)
ES (1) ES2970423T3 (enExample)
IL (1) IL272757B2 (enExample)
MX (2) MX2020002106A (enExample)
PL (1) PL3672622T3 (enExample)
SG (1) SG11202001544VA (enExample)
TW (1) TWI791040B (enExample)
WO (1) WO2019038685A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2773133A1 (en) * 2009-08-28 2011-03-03 Edward H. Schuchman Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
PL3672622T3 (pl) * 2017-08-24 2024-04-02 Genzyme Corporation Rekombinowana ludzka kwaśna sfingomielinaza do zastosowania w leczeniu nieprawidłowych stanów kości u pacjentów z niedoborem kwaśnej sfingomielinazy
PY1939780A (es) * 2018-05-25 2019-12-04 Genzyme Corp Composiciones farmacéuticas para el tratamiento de la deficiencia de esfingomielinasa ácida
JP7568648B2 (ja) * 2019-05-31 2024-10-16 ジェンザイム・コーポレーション 二次元ｌｃ－ｍｓ／ｍｓシステム
CN112773779B (zh) * 2021-02-04 2022-08-16 上海交通大学医学院附属新华医院 氨溴索、千金藤和汉防已在治疗酸性鞘磷脂酶缺乏症中的应用
TW202403043A (zh) * 2022-03-18 2024-01-16 美商健臻公司 重組人類酸性鞘磷脂酶醫藥組合物及方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773278A (en) 1991-05-03 1998-06-30 Mount Sinai Medical Center Acid sphingomyelinase gene
CN1302897A (zh) 1999-10-28 2001-07-11 上海博容基因开发有限公司 一种新的多肽——人酸性鞘磷酯酶相似的磷酸二酯酶21和编码这种多肽的多核苷酸
US8158582B2 (en) * 2005-06-02 2012-04-17 Tercica, Inc. Methods for treatment of insulin-like growth factor-1 deficiency
CA2773133A1 (en) * 2009-08-28 2011-03-03 Edward H. Schuchman Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
WO2013130963A1 (en) 2012-03-02 2013-09-06 Shire Human Genetic Therapies, Inc. Compositions and methods for treating type iii gaucher disease
AR093908A1 (es) 2012-12-12 2015-06-24 Teva Pharma Fusion de la hormona de crecimiento humana y albumina, formulacion y usos de la misma
MX370570B (es) * 2013-06-07 2019-12-17 Genzyme Corp Marcador para trastornos de la esfingomielinasa acida y sus usos.
PL3672622T3 (pl) * 2017-08-24 2024-04-02 Genzyme Corporation Rekombinowana ludzka kwaśna sfingomielinaza do zastosowania w leczeniu nieprawidłowych stanów kości u pacjentów z niedoborem kwaśnej sfingomielinazy

Also Published As

Publication number Publication date
CN118453843A (zh) 2024-08-09
JP2023052459A (ja) 2023-04-11
AU2018319565B2 (en) 2025-02-20
BR112020003541A2 (pt) 2020-09-01
WO2019038685A2 (en) 2019-02-28
MX2020002106A (es) 2020-07-14
AU2018319565A1 (en) 2020-04-09
IL272757B2 (en) 2024-07-01
NZ762860A (en) 2025-09-26
TWI791040B (zh) 2023-02-01
RU2020111649A (ru) 2021-09-24
JP2024050732A (ja) 2024-04-10
IL272757A (en) 2020-04-30
ES2970423T3 (es) 2024-05-28
IL272757B1 (en) 2024-03-01
US20240218338A1 (en) 2024-07-04
KR102769578B1 (ko) 2025-02-20
CA3073648A1 (en) 2019-02-28
JP7431356B2 (ja) 2024-02-14
EP3672622A2 (en) 2020-07-01
WO2019038685A3 (en) 2019-05-02
MX2023010908A (es) 2023-09-27
SG11202001544VA (en) 2020-03-30
JP2020531527A (ja) 2020-11-05
TW201919689A (zh) 2019-06-01
US20210139868A1 (en) 2021-05-13
JP7216075B2 (ja) 2023-01-31
EP3672622B1 (en) 2023-11-08
CN111344003B (zh) 2024-05-07
KR20250025051A (ko) 2025-02-20
CN111344003A (zh) 2020-06-26
AU2025203384A1 (en) 2025-05-29
KR20200044064A (ko) 2020-04-28
US11898175B2 (en) 2024-02-13
CO2020001801A2 (es) 2020-04-01

Similar Documents

Publication Publication Date Title
IL272757A (en) Treatment of abnormal bone condition in patients with sphingomyelin deficiency
HUE065585T2 (hu) Integrált sebészeti rendszer a szem szivárványhártya-szaruhártya szögletének kezelésére
IL261063A (en) Fixing staples for use in surgical procedures
EP3166487A4 (en) Bone reconstruction and orthopedic implants
ZA201907552B (en) Recombinant human acid alpha-glucosidase
IN2014DN08676A (enExample)
PL3283137T3 (pl) Biozgodne implanty do regeneracji nerwu i sposoby ich stosowania
IL257057A (en) Biologically active peptides derived from soy for use in preparations and methods for wound healing, tissue engineering and regenerative medicine
IL264301A (en) Treatment of Fabry disease in ert-naive and ert-experienced patients
EP3720368C0 (en) BONE FIXATION SET AND IMPLANTS
IL273470A (en) Semaglutide in medical treatment
ES3065184T3 (en) Use of migalastat for treating fabry disease in pregnant patients
EP3606570B8 (en) Collagen peptide-based medicament compositions for use in the treatment of ocular diseases, disorders or wounds
EP3253886A4 (en) Novel methods for early identification of bone healing ability in injured patients
PL3294279T3 (pl) Kompozycje zawierające aminokwasy do zastosowania w leczeniu zapalenia błony śluzowej u pacjentów cierpiących na neoplazję poddawanych radioterapii i/lub chemioterapii
SG11202000423XA (en) Treatment of fabry disease in ert-naïve and ert-experienced patients
GB201503967D0 (en) Biocompatible implants for use in tendon therapy
GB201519557D0 (en) Compounds for use in the treatment of telomere related diseases and/or telomere related medical conditions
IL277480A (en) Calcipidiol use in bariatric surgery patients
IL237117A0 (en) Dental implant for stabilization and ease of insertion into the implantation site
IL228155A0 (en) Orthopedic implant for the treatment of bone deformities
MX2025002733A (es) Composiciones farmaceuticas para el tratamiento de la deficiencia de esfingomielinasa acida
SG10201912497WA (en) A blood coagulation factor replacement product for use in the treatment or prophylaxis of bleedings
GB201812041D0 (en) Surgical implants and apparatus for use in surgery
PT3672622T (pt) Esfingomielinase ácida humana recombinante para utlização no tratamento de condições ósseas anormais em pacientes com deficiência de esfingomielinase ácida